Health benefits of ubiquinol

Health benefits  of  ubiquinol (8 times more Powerful than regular CoQ 10)

Professor Karl Folkers discovered the chemical structure of CoQ10 back in 1958. Coenzyme Q10 is a fat-soluble nutrient also known as CoQ10, or ubiquinone. It is primarily found in the mitochondria, which are small bodies within cells that produce energy for the body. Apart from the important process that provides energy, CoQ10 also stabilizes cell membranes and acts as an antioxidant (a substance that reduces damage that results from oxygen, such as is caused by free radicals).

Japan’s premier CoQ10 researcher Dr. Mae, developed a new form of CoQ10 that’s 8 times more powerful than regular CoQ10.

Traditionally, all CoQ10 supplements use the active ingredient ubiquinone. But once this gets into your system, your body must convert ubiquinone into another substance called ubiquinol.

Ubiquinol is the form of CoQ10 that works miracles. This new option provides 8 times higher absorption of CoQ10 and keeps your blood levels high over an extended period. And high blood levels are what you need to delay the effects of aging and the diseases they bring.

Not All Co Enzyme Q 10 is created Equal:

Scientists have found that the ubiquinol, the reduced form of Co Q 10, dramatically improves absorption of Co Q 10 in patients with severe heart failure compared to supplements of ubiquinone, the unreduced form of Co Q 10. In other findings, the high antioxidant status of ubiquinol has allowed it to significantly inhibit inflammation. And to top it off, prices for the more effective ubiquinol have come down to levels commensurate with those of the unreduced Co Q 10 supplements in the ubiquinone form.

Heart patients show dramatic increase in Co Q 10 levels with the ubiquinol form

Scientists at East Texas Medical Center and Trinity Mother Francis Hospital in Texas noted that patients with chronic heart failure often fail to achieve adequate plasma levels of unreduced Co Q 10 even at doses as high as 900 mg per day. As a result of this, they show limited clinical improvement in their condition. For their study, these scientists identified seven patients in advanced chronic heart failure with sub-therapeutic plasma Co Q 10 levels at a mean of 1.6 microg/ml on an average dose of unreduced Co Q 10 of 450 mg per day. All seven of these patients were changed to an average dose of 580 mg per day of ubiquinol.

Mean plasma Co Q 10 levels increased to an average of 6.5 microg/ml. Measurement with echocardiogram showed mean improvement from 22% to 39%. Clinical status was remarkably improved from a mean of class IV to a mean of class II. The researchers concluded that the ubiquinol form of Co Q 10 dramatically improved absorption in patients with severe heart failure, and the improvement in plasma Co Q 10 levels is correlated with clinical improvement and improvement in measurement of left ventricular function. This study is from the 2008 journal Biofactors.

Ubiquinol is more compatible with the needs of the body

Ubiquinol is the new, reduced from of the Co Q 10 supplement that has been on the market for many years. The substance Co Q 10 is a critical component of human metabolism and a dynamic nutrient that moves between two states, the oxidized ubiquinone, and the reduced ubiquinol. While in the ubiquinol state, its ability to be assimilated into the human body is increased, and it develops the additional feature of being a first class antioxidant.

Due to its critical role in metabolism, the body is able to make Co Q 10 on its own, although some Co Q 10 is also obtainable from the diet. Although it is naturally in all cells, Co Q 10 is particularly concentrated in tissues having high energy requirements like the heart, liver, lungs, and muscles of the skeleton. Smaller amounts are centered in the brain, kidneys, and intestines, and the rest is in general circulation for use as needed. A normal adult has Co Q 10 amounts in the range of 0.5 and 1.5 grams. Within each cell, at least half the amount is centered in the mitochondra, the furnace of the cells where food is turned into energy, and this is where the final stages of its synthesis occur.

The cycling action of Co Q 10 helps it achieve its metabolic goals. Ubiquinone (unreduced Co Q 10) picks up electrons and becomes ubiquinol. Ubiquinol releases electrons and becomes ubiquinone, and the cycle repeats. According to scientist Kevin Connolly Ph.D., the ability of Co Q 10 to move electrons around is a “fundamental step in the production of energy, in the regeneration of antioxidants in cell membranes, and in the construction of other important biological molecules.”

The electrons moved about by Co Q 10 aid in the chemical reactions that allow broken down sugars, fats and amino acids from food to be burned as fuel in the mitochondria and to produce adenosine triphosphate (ATP), the actual chemical energy that powers cellular workings. Without adequate amounts of Co Q 10, cellular workings grind to a halt. It is clear that both ubiquinone and ubiquinol are essential to the process.

Co Q 10 as ubinquinol also has a role as a membrane and lipid antioxidant. It works with vitamin E, lycopene and beta-carotene to prevent LDL oxidation by giving up electrons to other oxidized molecules in order to regenerate them. This process results in the conversion of ubiquinol back into ubiquinone, which must then be re-engaged. Since ubiquinol is a form of Co Q 10 that can convert into ubiquinone, all the benefits of Co Q 10 as ubiquinone are available in ubiquinol supplements with the additional benefits that are provided only by ubiquinol including its ease of assimilation into the body and super antioxidant status.

Ubiquinol recently found to have strong anti-inflammatory properties

Numerous investigations of Co Q 10 have been conducted since its discovery in 1957. Most have centered on its applications for cardiovascular health. In addition to those dealing with chronic heart failure, Co Q 10 has been studied for its role against exercise-induced angina, hypertension, and recovery from heart attack. Deficiencies of Co Q 10 have been implicated in cellular energy dysfunctions and neurological degeneration.

A study done at the University of Kiel in Germany and reported in January investigated the potential of Co Q 10 as an anti-inflammatory. Scientists studied the influence of the ubiquinol form on lipopolysaccharide (LPS) induced pro-inflammatory cytokines and chemokines in a monocytic cell line. They found LPS induced responses were significantly decreased by pre-incubation of cells with ubiquinol. This study is from the Journal of Clinical Biochemistry and Nutrition. It highlights the super antioxidant benefits of ubiquinol, benefits that are not available from the unbiquinone form of Co Q 10.

Dietary benefits of Co Q 10 are quite limited

Food sources of Co Q 10 are meat (particularly organ meats such as liver and heart), poultry, fish, nuts and seeds. Vegetables, eggs, and dairy products contain small amounts. Co Q 10 is also found in soybean and canola oils, however soybeans should be fermented before eating, and canola probably should not be consumed at all. Here are the milligram amounts of Co Q 10 found in food:

Beef, fried 3 ounces 2.6
Herring, marinated 3 ounces 2.3
Chicken, fried 3 ounces 1.4
Rainbow Trout, steamed 3 ounces 0.9
Peanuts, roasted 1 ounce 0.8
Sesame seeds, roasted 1 ounce 0.7
Pistachio nuts, roasted 0.9
Broccoli, boiled 4 ounces chopped 0.5
Orange, 1 medium 0.3
Strawberries, 4 ounces 0.1
Egg, 1 medium boiled 0.1

As these numbers reveal, people were meant to manufacture Co Q 10 in the body rather than obtain it from the diet. On top of dietary amounts being minuscule, Co Q 10 from the diet is poorly absorbed by the body. For people seeking to boost sagging energy levels and support their hearts, supplements of the ubiquinol form of Co Q 10 are clearly the most effective option.

Ubiquinol is ready for absorption into the lymphatic system

Studies have measured absorption of supplemental Co Q 10 in the ubiquinone form at levels as low as two to three percent of the total amount ingested. The recent development of a stabilized dose of ubiquinol in supplement form is viewed by scientists as an exciting development because of its ease of absorption. Co Q 10 as ubiquinone must be reduced to ubiquinol before it can be released into the lymphatic system. Supplements of ubiquinol being already reduced are ready for absorption into the lymphatic system, and this may be why ubiquinol based Co Q 10 supplements exhibit enhanced bioavailability over those that are ubquinone based.

Supplementing with ubiquinol becomes more important as people age

Declines in ubiquinol result in less cellular energy and diminished protection against oxidative stress. This stress produces free radicals that can damage proteins, fats and DNA, allowing degenerative diseases to get started. Studies have reported dramatic decreases in Co Q 10 levels and increased oxidative stress associated with the aging process and with many age-related conditions. Healthy people in their 20s readily produce all the Co Q 10 they can use and efficiently convert it into ubiquinol. This ability becomes hindered as years go by through metabolic demands and oxidative stress. The decline in endogenous production of Co Q 10 and the ability to convert it into ubiquinol is apparent in 40 year olds.

For people age 40 and older, supplementing with ubiquinol is important for supporting and maintaining cardiovascular, neurological and liver health. Supplements of ubiquinol may restore healthy levels of Co Q 10 in plasma and organs for more efficient energy production, resulting in increased energy and stamina as well as better overall health. And because it is a powerful antioxidant, ubiquinol offers defense against oxidative stress and age-related conditions. Restoring this vital nutrient to optimal levels can result in people experiencing the energy levels they had when much younger.

Ubiquinol found safe in initial study

Ubiquinol as a supplement has been on the market only since 2006. The safety and bioavailability of ubiquinol were evaluated for the first time in February, 2007. Healthy subjects were administered a single oral dose of 150 or 300 mg, and additional oral administration of 90, 150, and 300 mg doses for four weeks. No clinically relevant negative changes were observed in laboratory tests, physical examinations, vital signs, or ECG. Significant absorption from the gastrointestinal tract was observed. This study was reported in Regulatory Toxicology and Pharmacology and shows that initial testing found ubiquinol safe and highly bioavailable to the body.

There is currently only one manufacturer of ubiquinol. This means that whether you pay a lot or a little, you are getting the same ubiquinol compound when you buy ubiquinol supplements. The only variation is in the milligram amount in the capsules.

Co Q 10 is a lipophilic, meaning it dissolves in fat, so supplements of Co Q 10 as ubiquinol should always be taken with some type of dietary fat.

Patients suffering from advanced congestive heart failure exhibited significantly improved heart function after supplementing with ubiquinol, according to a recent clinical trial. Ubiquinol, only available in supplement form since late 2006, is the active antioxidant form of Coenzyme Q10 (CoQ10). CoQ10, a vitamin-like substance found in every cell in the body, plays a vital role in cellular energy production and protects cells from free radical damage.

In the first clinical trial evaluating ubiquinol effects on late-stage congestive heart failure, cardiologist Peter Langsjoen found that critically ill patients who supplemented with ubiquinol for just three months experienced a 24 to 50 percent increase in their hearts’ ability to pump blood. In some cases, patients’ plasma levels of CoQ10, which are key to overall heart health, more than tripled. At the start of the study, each of the patients evaluated had a life expectancy of less than six months. However, all demonstrated significantly improved heart function by the trial’s end, and survived past initial expectations.

“The effects of ubiquinol on late-stage heart failure patients resulted in striking improvements beyond anything I’ve seen in 25 years of cardiology practice,” said Dr. Langsjoen, who conducted the research in Tyler, Texas. “It is my strong feeling that this ubiquinol product is a major breakthrough.”

Scientists at Kaneka Corporation, the world’s largest manufacturer of CoQ10, developed the method to produce ubiquinol, commercially available as KanekaQH™, for supplemental use. Because the reduced ubiquinol reverts back to CoQ10 when exposed to air and light, the process of stabilizing the nutrient outside of the body took more than a decade to test and perfect before it was launched a little more than a year ago.

“Over the last several years, our team of scientists have documented that KanekaQH can be several times more absorbable than CoQ10, but to see that higher bioavailability translate into such staggering improvements in these patients’ lives is particularly gratifying,” said Dr. Robert Barry of Kaneka Nutrients, L.P., who recently released a book entitled The Power of KanekaQH™ (Ubiquinol): The Key to Energy, Vitality and a Healthy Heart in which he documents some of the most intriguing research to date on CoQ10 and ubiquinol in regards to aging and heart health.

The oxidized form of CoQ10, ubiquinone, was first used as a dietary supplement for cardiac patients in Japan 40 years ago. It has since gained popularity worldwide for the many health and condition-specific benefits identified in the thousands of studies conducted since its discovery in 1957.

Two forms of CoQ10: Ubiquinone and Ubiquinol

Both ubiquinone and ubiquinol are essential to generating cellular energy and sustaining life; however, the reduced form, ubiquinol, is responsible for the powerful antioxidant benefits associated with CoQ10. More than 90 percent of the CoQ10 found in a healthy person’s plasma is in its reduced ubiquinol form.

For the past 40 years, only ubiquinone was available as a supplement. KanekaQH™, the world’s only supplemental ubiquinol, has only been available for the past year. The ingredient, manufactured exclusively by Kaneka, is currently available in more than 30 consumer supplements and is the subject of a number of new trials expected to begin in 2008.

“Cardiovascular patients, those fighting age-related diseases and even healthy people over the age of 40 have a critical need to optimize plasma CoQ10 levels within their bodies,” explained Dr. Barry. “Because it’s so much better absorbed by the body, KanekaQH™ can raise CoQ10 levels more effectively and, as we’re seeing from Dr. Langsjoen’s study, can have tremendous health impact on those suffering from debilitating diseases.”

An abstract of Dr. Langsjoen’s supplemental ubiquinol study is available at http://www.kanekaqh.com/clinicaltrials. Full results of the study are expected to be published in a major scientific journal in 2008.

For More REFERENCES on Coenzyme Q 10:

1.   Gian Paolo Littarru (1994) Energy and Defense. Facts and

perspectives on CoenzymeQ10 in biology and medicine. Casa

Editrice Scientifica Internazionale, pp 1-91.

2.   Crane F.L., Hatefi Y., Lester R.I., Widmer C. (1957)

Isolation of a quinone from beef heart mitochondria.   In:

Biochimica et Biophys. Acta, vol. 25, pp 220-221.

3.   Morton R.A., Wilson G.M., Lowe J.S., Leat W.M.F. (1957)

Ubiquinone.  In:  Chemical Industry,  pp 1649.

4.   Mellors A., Tappel A.L. (1966) Quinones and quinols as

inhibitors of lipid peroxidation.  Lipids, vol. 1, pp 282-284.

5.   Mellors A., Tappel A.L. (1966) The inhibition of

mitochondrial peroxidation by ubiquinone and ubiquinol.  J.

Biol. Chem., vol. 241, pp 4353-4356.

6.   Littarru G.P., Ho L., Folkers K. (1972) Deficiency of

Coenzyme Q10 in human heart disease.  Part I and II.  In:

Internat. J. Vit. Nutr. Res., 42, n. 2, 291:42, n. 3:413.

7.   Mitchell P. (1976) Possible molecular mechanisms of the

protonmotive function of cytochrome systems.  In:  J.

Theoret. Biol., vol. 62, pp 327-367.

8.   Mitchell P. (1991) The vital protonmotive role of coenzyme

Q.  In:  Folkers K., Littarru G.P., Yamagami T. (eds)

Biomedical and Clinical Aspects of Coenzyme Q, vol. 6,

Elsevier, Amsterdam, pp 3-10.

9.   Mitchell P. (1988) Respiratory chain systems in theory and

practice.  In:  Advances in Membrane Biochemistry and

Bioenergetics, Kim C.H., et al. (eds), Plenum Press, New

York, pp 25-52.

10.  Mitchell P. (1979) Kelin’s respiratory chain concept and its

chemiosmotic consequences. In: Journal Science, vol. 206,

pp 1148-1159.

11.   Ernster L. (1977) Facts and ideas about the function of

coenzyme Q10 in the Mitochondria.  In:  Folkers K.,

Yamamura Y. (eds)  Biomedical and Clinical Aspects of

Coenzyme Q. Elsevier, Amsterdam, pp 15-8.

12.   Littarru G.P., Lippa S., Oradei A., Fiorni R.M., Mazzanti L.

Metabolic and diagnostic implications of blood CoQ10 levels.

In: Biomedical and Clinical Aspects of Coenzyme Q, vol. 6

(1991) Folkers K., Yamagami T., and Littarru G. P. (eds)

Elsevier, Amsterdam, pp 167-178.

13.   Ghirlanda G., Oradei A., Manto A., Lippa S., Uccioli L.,

Caputo S., Greco A.V., Littarru G.P. (1993) Evidence of

Plasma CoQ10 – Lowering Effect by HMG-CoA Reductase

Inhibitors: A double blind , placebo-controlled study.  Clin.

Pharmocol., J. 33, 3, 226-229.

14.   Folkers K., Langsjoen Per H.,Willis R., Richardson P., Xia

L.,Ye C., Tamagawa H. (1990) Lovastatin decreases

coenzyme Q levels in humans.  Proc. Natl. Acad Sci. Vol.

87, pp.8931-8934.

15.   Folkers K., Vadhanavikit S., Mortensen S.A. (1985)

Biochemical rationale and myocardial tissue data on the

effective therapy of cardiomyopathy with coenzyme Q10.  In:

Proc. Natl. Acad. Sci., U.S.A., vol. 82(3), pp 901-904.

16.   Mortensen S.A., Vadhanavikit S., Folkers K. (1984)

Deficiency of coenzyme Q10 in myocardial failure.  In:

Drugs Exptl. Clin. Res. X(7) 497-502.

17.   Hiasa Y., Ishida T., Maeda T., Iwanc K., Aihara T., and Mori

H. (1984) Effects of coenzyme Q10 on exercise tolerance in

patients with stable angina pectoris.  In:   Biomedical and

Clinical Aspects of Coenzyme Q, vol. 4 (1984) Folkers K.,

Yamamura Y., (eds) Elsevier, Amsterdam, pp 291-301.

18.   Kamikawa T., Kobayashi A., Yamashita T., Hayashi H., and

Yamazaki N. (1985) Effects of coenzyme Q10 on exercise

tolerance in chronic stable angina pectoris.  In:  Am. J.

Cardiol.; 56:247-251.

19.   Langsjoen Per.H., Vadhanavikit S., Folkers K. (1985)

Response of patients in classes III and IV of cardiomyopathy

to therapy in a blind and crossover trial with coenzyme Q10.

In:  Proc. Natl.  Acad. of Sci., U.S.A., vol. 82, pp 4240-4244.

20.   Judy W.V., Hall J.H., Toth P.D., Folkers K. (1986) Double

blind-double crossover study of coenzyme Q10 in heart

failure.  In:  Folkers K., Yamamura Y. (eds) Biomedical and

clinical aspects of coenzyme Q, vol. 5.  Elsevier,

Amsterdam, pp 315-323.

21.   Rossi E., Lombardo A., Testa M., Lippa S., Oradei A.,

Littarru G.P., Lucente M. Coppola E., Manzoli U.  Coenzyme

Q10 in ischaemic cardiopathy. In:  Biomedical and Clinical

Aspects of Coenzyme Q, vol. 6 (1991) Folkers K., Yamagami

T., and Littarru G. P. (eds) Elsevier, Amsterdam, pp 321-326.

22.   Morisco C., Trimarco B., Condorelli M.  Effect of coenzyme

Q10 therapy in patients with congestive heart failure: A

long-term multicenter randomized study.  In:  Seventh

International Symposium on Biomedical and Clinical Aspects

of Coenzyme Q  Folkers K., Mortensen S.A., Littarru G.P.,

Yamagami T., and Lenaz G. (eds) The Clinical Investigator,

(1993) 71:S  34-S 136.

23.   Schneeberger W., Muller-Steinwachs J., Anda L.P., Fuchs

W., Zilliken F., Lyson K., Muratsu K., and Folkers K. A

clinical double blind and crossover trial with coenzyme Q10

on patients with cardiac disease.  In:  Biomedical and

Clinical Aspects of Coenzyme Q, vol. 5 (1986) Folkers K.,

Yamamura Y., (eds) Elsevier, Amsterdam, pp 325-333.

24.   Schardt F., Welzel D., Schiess W., and Toda K. Effect of

coenzyme Q10 on ischaemia-induced ST-segment depression:

A double blind, placebo-controlled crossover study.  In:

Biomedical and Clinical Aspects of Coenzyme Q, vol. 6

(1991) Folkers K., Yamagami T., and Littarru G. P. (eds)

Elsevier, Amsterdam, pp 385-403.

25.   Swedberg K., Hoffman-Berg C., Rehnqvist N., Astrom H.

(1991) Coenzyme Q10 as an adjunctive in treatment of

congestive heart failure.  In: 64th Scientific Sessions

American Heart Association, Abstract 774-6.

26.   Biomedical and Clinical Aspects of Coenzyme Q. (1977)

Folkers K., Yamamura Y. (eds) Elsevier, Amsterdam, pp 1-315.

27.   Biomedical and Clinical Aspects of Coenzyme Q, Vol. 2

(1980) Yamamura Y., Folkers K., and Ito Y. (eds) Elsevier,

Amsterdam, pp 1-456.

28.   Biomedical and Clinical Aspects of Coenzyme Q, Vol. 3

(1981) Folkers K., Yamamura Y., (eds) Elsevier,

Amsterdam, pp 1-414.

29.   Biomedical and Clinical Aspects of Coenzyme Q , Vol. 4

(1983) Folkers K., Yamamura Y., (eds) Elsevier,

Amsterdam, pp 1-432.

30.   Biomedical and Clinical Aspects of Coenzyme Q, Vol. 5

(1986) Folkers K., Yamamura Y., (eds) Elsevier,

Amsterdam, pp 1-410.

31.   Biomedical and Clinical Aspects of Coenzyme Q, Vol. 6

(1991) Folkers K., Yamagami T., and Littarru G. P. (eds)

Elsevier, Amsterdam, pp 1-555.

32.   Seventh International Symposium on Biomedical and Clinical

Aspects of Coenzyme Q (1993) Folkers K., Mortensen S.A.,

Littarru G.P., Yamagami T., and Lenaz,G. (eds) The Clinical

Investigator, Supplement to Vol.71 /  Issue 8, pp S51-S177.

33.   Eighth International Symposium on Biomedical and Clinical

Aspects of Coenzyme Q (1994) Littarru G.P., Battino M. ,

Folkers K. (Eds) The Molecular Aspects of Medicine, Vol.

15 (Supplement), pp S1-S294.

34.   Spigset O. (1994) Reduced effect of warfarin caused by

ubidecarenone.  Lancet  Nov 12 Vol. 344, pp. 8933.

35.   Mortensen S.A., Vadhanavikit S., Folkers K. (1984)

Deficiency of coenzyme Q10 in myocardial failure. In: Drugs

Exptl. Clin. Res., vol. X(7), pp 497-502.

36.   Mortensen S.A., Vadhanavikit S., Baandrup U., Folkers K.

(1985) Long term coenzyme Q10 therapy:  a major advance in

the management of resistant myocardial failure. In: Drugs

Exp. Clin. Res., vol.11(8), pp 581-593.

37.   Langsjoen P.H., Folkers K., Lyson K., Muratsu K., Lyson T.,

Langsjoen P. H.  Effective and safe therapy with coenzyme

Q10 for cardiomyopathy.  In:  Klin. Wochenschr. (1988)

66:583-593.

38.   Langsjoen P. H., Langsjoen, P. H., Folkers, K. (1989) Long

term efficacy and safety of coenzyme Q10 therapy for

idiopathic dilated cardiomyopathy.  In:  The American

Journal of Cardiology, Vol. 65, pp 521 – 523.

39.   Mortensen S.A., Vadhanavikit S., Muratsu K., Folkers K.

(1990) Coenzyme Q10:  Clinical benefits with biochemical

correlates suggesting a scientific breakthrough in the

management of chronic heart failure.  In:  Int. J. Tissue

React., Vol. 12 (3), pp 155-162.

40.   Ursini T., Gambini C., Paciaroni E., and Littarru G.P.

Coenzyme Q10 treatment of heart failure in the elderly:

Preliminary results.  In: Biomedical and Clinical Aspects of

Coenzyme Q, vol. 6 (1991) Folkers K., Yamagami T., and

Littarru G. P. (eds) Elsevier, Amsterdam, pp 473-480.

41.   Poggessi L., Galanti G., Comeglio M., Toncelli L., Vinci M.

(1991) Effect of coenzyme Q10 on left ventricular function in

patients with dilative cardiomyopathy.  Curr. Ther. Res.

49:878-886.

42.   Langsjoen H.A., Langsjoen P. H., Langsjoen P. H., Willis R.,

Folkers K. (1994) Usefulness of coenzyme Q10 in clinical

cardiology, a long-term study.  In: Eighth International

Symposium on Biomedical and Clinical Aspects of

Coenzyme Q, Littarru G.P., Battino M. , Folkers K. (Eds)

The Molecular Aspects of Medicine, Vol. 15 (Supplement),

pp S165-S175.

43.   Baggio E., Gandini R., Plancher A.C., Passeri M., Carmosino

G.  Italian multicenter study on safety and efficacy of

coenzyme Q10 adjunctive therapy in heart failure. In:  Eighth

International Symposium on Biomedical and Clinical Aspects

of Coenzyme Q (1994) Littarru G.P., Battino M. , Folkers K.

(Eds) The Molecular Aspects of Medicine, Vol. 15

(Supplement), pp S287-S294.

44.   Langsjoen Per H., Langsjoen Peter H., Folkers K.  Isolated

diastolic dysfunction of the myocardium and its response to

CoQ10 treatment. In:  Seventh International Symposium on

Biomedical and Clinical Aspects of Coenzyme Q.  Folkers,

K., Mortensen S.A., Littarru G.P., Yamagami T., and Lenaz

G. (eds) The Clinical Investigator, (1993) 71:S 140-S 144.

45.   Oda T.  Recovery of the Frank-Starling mechanism by

coenzyme Q10 in patients with load-induced contractility

depression.  In:  Eighth International Symposium on

Biomedical and Clinical Aspects of Coenzyme Q (1994)

Littarru G.P., Battino M., Folkers K. (Eds) The Molecular

Aspects of Medicine, Vol.15 (Supplement), pp S149-S154.

46.   Langsjoen P. H., Langsjoen P. H., Willis R., Folkers K.

(1994) Treatment  of essential hypertension with coenzyme

Q10.  In:  Eighth International Symposium on Biomedical and

Clinical Aspects of Coenzyme Q (1994) Littarru G.P.,

Battino M. , Folkers K. (Eds) The Molecular Aspects of

Medicine, Vol. 15 (Supplement), pp S287-S294.

47.   Pihko H., Saarinen U., and Paetau A. (1989)  Wernicke

encephalopathy – a preventable cause of death: Report of 2

children with malignant disease.  Pediatric Neurology vol. 5

no. 4, pp 237-242.

48.   Hansen I.L. (1976) Bioenergetics in clinical medicine.

Gingival leucocytic deficiencies of coenzyme Q10 in patients

with periodontal disease.  In:  Research Communications in

Chemical Pathology and Pharmacology, vol. 14, no. 4,

pp 729-738.

49.   Iwamoto Y., Watanabe T., Okamoto H., Ohata N., Folkers K.

Clinical effect of coenzyme Q10 on periodontal disease.  In:

Folkers, K., Yamamura, Y., (eds)  Biomedical and Clinical

Aspects of Coenzyme Q10, (1981) vol. 3, Elsevier,

Amsterdam, pp 109-119.

50.   Folkers K., Langsjoen P. H.,  et al. (1988) Biochemical

deficiencies of coenzyme Q10 in HIV-infection and the

exploratory treatment.  Biochemical and Biophysical

Research Communications vol. 153, no. 2, pp 888-896.

51.   Langsjoen P. H., Langsjoen P. H., Folkers K., Richardson P.

Treatment of patients with human immunodeficiency virus

infection with coenzyme Q10.  In:  Folkers K., Littarru G.P.,

and Yamagami, T., (eds) Biomedical and Clinical Aspects of

Coenzyme Q, (1991) vol. 6, pp 409-415.

52.   Cortes E.P, Mohinder G., Patel M., Mundia A., and Folkers

K.  Study of Administration of coenzyme Q10 to Adriamycin

treated cancer patients.  In:Biomedical and Clinical Aspects

of Coenzyme Q (1977).  Folkers K., Yamamura Y. (eds)

Elsevier, Amsterdam, pp 267-273.

53.   Combs A.B., Faria D.T., Leslie S.W., and Bonner H.W.

(1981) Effect of coenzyme Q10 on Adriamycin induced

changes in myocardial calcium.  In: Biomedical and Clinical

Aspects of Coenzyme Q, vol. 3  Folkers, K., Yamamura Y.,

(eds) Elsevier, Amsterdam, pp 137-144.

54.   Judy W.V. Hall J., H., Dugan W., Toth P.D., and Folkers K.

Coenzyme Q10 reduction of Adriamycin toxicity.  In:

Biomedical and Clinical Aspects of Coenzyme Q (1983),

vol. 4  Folkers K., Yamamura Y., (eds) Elsevier, Amsterdam,

pp 231-241.

55.   Lockwood K., Moesgaard S., Yamamoto T., Folkers K.

Progress on therapy of breast cancer with vitamin Q10 and

the regression of metastases. Biochem Biophys Res Commun

1995 Jul 6;212(1):172-7.

56.   Lockwood K., Moesgaard S., Hanioka T., Folkers K.

Apparent partial remission of breast cancer in ‘high risk’

patients supplemented with nutritional antioxidants, essential

fatty acids and coenzyme Q10.  Mol Aspects Med 1994;15

Suppl:s231-40.

57.   Lockwood K., Moesgaard S., Folkers K.   Partial and

complete regression of breast cancer in patients in relation to

dosage of coenzyme Q10.  Biochem Biophys Res Commun

1994 Mar 30;199(3):1504-8.

58.   Folkers K., Brown R., Judy W.V., and Morita M. (1993)

Survival of cancer patients on therapy with coenzyme Q10.

Biochem. Biophys. Res. Comm., Ms. No. G-8658.

59.   Mellstedt H., Osterborg A., Nylander M., Morita M., and

Folkers K.  A deficiency of coenzyme Q10 (CoQ10) in

conventional cancer therapy and blood levels of CoQ10 in

cancer patients in Sweden.  In:  Eighth International

Symposium on Biomedical and Clinical Aspects of

Coenzyme Q (1994) The Molecular Aspects of Medicine, in

print.

60.   Bowry V.W., Mohr D., Cleary J., Stocker R.  (1995)

Prevention of tocopherol-mediated peroxidation in

ubiquinol-10-free human low density lipoprotein.  J Biol

Chem 1995 Mar 17;270(11):5756-63.

61.   Ingold K.U., Bowry V.W., Stocker R., Walling C. (1993)

Autoxidation of lipids and antioxidation by alpha-tocopherol

and ubiquinol in homogeneous solution and in aqueous

dispersions of lipids: unrecognized consequences of lipid

particle size as exemplified by oxidation of human low

density lipoprotein. Proc Natl Acad Sci U S A 1993 Jan

1;90(1):45-9.

62.   Sun I.L., Sun E.E., Crane F.L., Morre, V.J., Lindgren A., and

Low H.  Requirement for coenzyme Q in plasma membrane

electron transport.  In:  Proc. Nat. Acad. Sci. U SA  89,

11126-11130 (1992).

63.   Linnane A.W., Zhang C., Baumer A., Nagley P. (1992)

Mitochondrial DNA mutation and the aging process:

bioenergy and pharmacological intervention. Mutation

Research 275, pp. 195-208.

64.   Martinius R.D., Linnane A.W., Nagley P. (1993) Growth of

human namalwa cells lacking oxidative phosphorylation can

be sustained by redox compounds potassium ferricyanide or

coenzyme Q10 putatively acting through the plasma

membrane oxidase.  In:  Biochem. Mol. Biol. Internat. 31,

997-1005.

65.   Lawin A., Martinius R.D., McMullen G., Nagley P., Vaillant

F., Wolvetang E. J., Linnane A.W.  The universality of

bioenergetic disease: The role of mitochondrial DNA

mutation and the putative inter-relationship between

mitochondria and plasma membrane NADH oxidases.  In:

Eighth International Symposium on Biomedical and Clinical

Aspects of Coenzyme Q (1994) Littarru G.P., Battino M. ,

Folkers K. (Eds) The Molecular Aspects of Medicine, Vol.

15 (Supplement), pp S13-S27.